세계의 바이오시뮬레이션 시장 규모, 점유율, 동향 분석 : 제품별, 가격 모델별, 최종 용도별, 용도별, 전개 모델별, 치료 분야별, 지역별 전망 및 예측(2024-2031년)

The Global Biosimulation Market size is expected to reach $11.16 billion by 2031, rising at a market growth of 16.7% CAGR during the forecast period.

The North America segment acquired 47% revenue share in the market in 2023. This preeminence can be ascribed to the region's sophisticated healthcare infrastructure, substantial investments in pharmaceutical and biotechnology research, and the prompt integration of innovative technologies. The presence of prominent industry stakeholders, in conjunction with substantial governmental support for pharmaceutical development and personalized medicine, has significantly accelerated market expansion in this region.

Advancements in computational modeling and simulation techniques have transformed this by significantly enhancing the accuracy and efficiency of models through the integration of artificial intelligence (AI) and machine learning (ML). These technologies enable researchers to analyze vast datasets, uncover patterns, and predict biological behaviors critical for drug discovery and development. Hence, these advancements will aid in the expansion of the market.

Additionally, Minimizing clinical trial failures is essential for pharmaceutical companies due to drug development's high costs and time. They offers a powerful solution by predicting trial outcomes and identifying potential risks before trials begin. Through advanced computational modeling, researchers can simulate drug interactions and biological responses in virtual environments, allowing them to refine trial designs and mitigate risks. Thus, as its applications expand, this is becoming integral to modern drug development, driving efficiency and innovation in the pharmaceutical industry.

Moreover, The COVID-19 pandemic presented initial challenges to this market, as disruptions to clinical trials and research activities delayed data collection and hindered the development of accurate models. With restrictions in place and resources redirected toward immediate pandemic response efforts, many pharmaceutical and biotechnology companies had to scale back investments in this for non-COVID-related projects. Additionally, economic uncertainties and budget constraints, particularly for smaller organizations, further slowed the adoption of these technologies in the early stages of the pandemic. Thus, the pandemic had an overall positive impact on the market.

However, these platforms and tools often require substantial financial investment for initial software acquisition and the accompanying infrastructure needed for seamless deployment. These tools are designed to simulate complex biological processes, which demand advanced algorithms, robust computational power, and regular updates to remain effective. Hence, without strategies to make these solutions more affordable or accessible, this cost barrier will continue to restrict the adoption of these technologies across broader segments of the healthcare and research industries.

Product Outlook

Based on product, the market is bifurcated into software and services. The services segment procured 40% revenue share in the market in 2023. The growth of the services segment is fueled by the rising complexity of drug development processes and the increasing reliance on expert consulting and technical support. These services assist organizations in navigating these challenges by offering model customization, validation, and training.

Pricing Model Outlook

On the basis of pricing model, the market is divided into license-based model, subscription-based model, service-based model, and pay per use model. The service-based model segment witnessed 19% revenue share in the market in 2023. This model gives organizations access to this expertise and infrastructure as needed, allowing them to avoid high upfront costs associated with purchasing software or building in-house capabilities. The flexibility of the service-based model is especially appealing to smaller companies and start-ups, which may lack the resources to invest in standalone software.

End Use Outlook

By end use, the market is classified into life sciences companies, academic research institutions, and others. The academic research institutions segment procured 32% revenue share in the market in 2023. Academic institutions are instrumental in the advancement of these technologies through the execution of foundational research and the development of innovative models for the examination of biological systems. These institutions often collaborate with industry players to refine and validate simulation tools, making them a key stakeholder in this ecosystem.

Application Outlook

On the basis of application, the market is classified into drug discovery & development, disease modeling, and others. The drug discovery & development segment acquired 55% revenue share in the market in 2023. These tools have revolutionized drug discovery by enabling researchers to model complex biological systems, predict drug interactions, and optimize formulations before conducting physical experiments. This significantly reduces the time and cost of bringing new drugs to market.

Deployment Model Outlook

Based on deployment model, the market is segmented into cloud-based, on-premises, and hybrid model. The on-premises segment acquired 35% revenue share in the market in 2023. Organizations handling sensitive proprietary data or operating in regions with strict data privacy laws often prefer on-premises solutions to retain complete control over their biosimulation processes. For example, large pharmaceutical companies like Novartis rely on on-premises biosimulation tools to manage proprietary drug development data, ensuring adherence to industry-specific standards like HIPAA and GDPR.

Therapeutic Area Outlook

By therapeutic area, the market is divided into oncology, cardiovascular disease, infectious disease, neurological disorders, and others. The cardiovascular disease segment garnered 26% revenue share in the market in 2023. They plays a crucial role in designing and optimizing therapies for these complex disorders by modeling drug effects on the cardiovascular system. For instance, this was pivotal in developing novel anticoagulants like apixaban (Eliquis), which helped predict safety profiles and efficacy in preventing stroke in patients with atrial fibrillation.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe segment recorded 26% revenue share in the market in 2023. European countries, particularly Germany, the United Kingdom, and France, have witnessed substantial investments in these tools to enhance drug discovery and optimize clinical trial designs. The region's emphasis on sustainability and precision medicine, along with supportive policies for digital transformation in healthcare, has accelerated the adoption of these technologies.

Recent Strategies Deployed in the Market

• Oct-2024: Certara, Inc. completed the acquisition Chemaxon, a provider of in-silico research software for life sciences, to integrate precision chemistry tools into Certara's biosimulation platforms. Chemaxon, known for products like JChem Engines, complements Certara's Simcyp PBPK Simulator and Certara.AI. The collaboration aims to improve prediction accuracy in drug discovery, especially for precision medicine therapies, while enhancing scientific innovation and productivity in the life sciences sector.
• Aug-2024: Certara, Inc. launched Phoenix(TM) version 8.5, an advanced PK/PD and toxicokinetic modeling platform used globally by pharmaceutical companies and regulators like the U.S. FDA. Enhancements include centralized cloud sign-in, improved reporting customization, and refined non-linear mixed effects modeling (NLME) tools. These updates streamline workflows, improve precision, and enhance data interpretation, aligning with Certara's mission to accelerate drug development and regulatory review processes.
• Jun-2024: Simulations Plus, Inc. acquired Pro-ficiency, a provider of AI-powered simulation tools for clinical and commercial drug development, for $100 million. This acquisition broadens Simulations Plus's capabilities to cover pre-clinical to commercialization stages, integrating clinical trial operations and training. Pro-ficiency, previously backed by QHP Capital, specializes in immersive simulation learning and data-driven insights, complementing Simulations Plus's biosimulation expertise and expanding its market opportunities.
• May-2024: Simulations Plus, Inc. launched GastroPlus(R) X (GPX(TM)), an advanced PBPK/PBBM platform. GPX introduces machine learning, streamlined workflows, and intuitive design for applications like drug absorption and first-in-human outcomes. The platform supports regulatory interactions, aligning with initiatives like the FDA's Quantitative Medicine Center of Excellence. The launch underscores Simulations Plus's commitment to innovation and global market expansion.
• Apr-2024: Certara, Inc. launched Certara Cloud, the unifying platform that integrates its many scientific software solutions. Certara Cloud enhances the customer experience for clients that utilize multiple Certara products. Additionally, it enables Certara to both integrate with and launch interoperable software solutions that span Certara's customers' workflows from discovery to submission.

List of Key Companies Profiled

• Certara, Inc.
• Dassault Systemes SE
• Advanced Chemistry Development, Inc.
• Genedata AG (Danaher Corporation)
• Instem Group of Companies
• Chemical Computing Group ULC
• Simulations Plus, Inc.
• Schrodinger, Inc.
• PPD, Inc. (Thermo Fisher Scientific, Inc.)
• Physiomics Plc

Global Biosimulation Market Report Segmentation

By Product

• Software
  • Molecular Modeling & Simulation Software
  • Clinical Trial Design Software
  • PK/PD Modeling and Simulation Software
  • Pbpk Modeling and Simulation Software
  • Toxicity Prediction Software
  • Other Software Type
• Services
  • Contract Services
  • Consulting
  • Other Services Type

By Pricing Model

• License-based Model
• Subscription-based Model
• Service-based Model
• Pay Per Use Model

By End Use

• Life Sciences Companies
• Academic Research Institutions
• Other End Use

By Application

• Drug Discovery & Development
• Disease Modeling
• Other Application

By Deployment Model

• Cloud-based
• On-premises
• Hybrid Model

By Therapeutic Area

• Oncology
• Cardiovascular Disease
• Infectious Disease
• Neurological Disorders
• Other Therapeutic Area

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Biosimulation Market, by Product
  • 1.4.2 Global Biosimulation Market, by Pricing Model
  • 1.4.3 Global Biosimulation Market, by End Use
  • 1.4.4 Global Biosimulation Market, by Application
  • 1.4.5 Global Biosimulation Market, by Deployment Model
  • 1.4.6 Global Biosimulation Market, by Therapeutic Area
  • 1.4.7 Global Biosimulation Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges

Chapter 4. Competition Analysis - Global

• 4.1 Market Share Analysis, 2023
• 4.2 Strategies Deployed in Biosimulation Market
• 4.3 Porter Five Forces Analysis

Chapter 5. Global Biosimulation Market by Product

• 5.1 Global Software Market by Region
• 5.2 Global Biosimulation Market by Software Type
  • 5.2.1 Global Molecular Modeling & Simulation Software Market by Region
  • 5.2.2 Global Clinical Trial Design Software Market by Region
  • 5.2.3 Global PK/PD Modeling and Simulation Software Market by Region
  • 5.2.4 Global Pbpk Modeling and Simulation Software Market by Region
  • 5.2.5 Global Toxicity Prediction Software Market by Region
  • 5.2.6 Global Other Software Type Market by Region
• 5.3 Global Services Market by Region
• 5.4 Global Biosimulation Market by Services Type
  • 5.4.1 Global Contract Services Market by Region
  • 5.4.2 Global Consulting Market by Region
  • 5.4.3 Global Other Services Type Market by Region

Chapter 6. Global Biosimulation Market by Pricing Model

• 6.1 Global License-based Model Market by Region
• 6.2 Global Subscription-based Model Market by Region
• 6.3 Global Service-based Model Market by Region
• 6.4 Global Pay Per Use Model Market by Region

Chapter 7. Global Biosimulation Market by End Use

• 7.1 Global Life Sciences Companies Market by Region
• 7.2 Global Academic Research Institutions Market by Region
• 7.3 Global Other End Use Market by Region

Chapter 8. Global Biosimulation Market by Application

• 8.1 Global Drug Discovery & Development Market by Region
• 8.2 Global Disease Modeling Market by Region
• 8.3 Global Other Application Market by Region

Chapter 9. Global Biosimulation Market by Deployment Model

• 9.1 Global Cloud-based Market by Region
• 9.2 Global On-premises Market by Region
• 9.3 Global Hybrid Model Market by Region

Chapter 10. Global Biosimulation Market by Therapeutic Area

• 10.1 Global Oncology Market by Region
• 10.2 Global Cardiovascular Disease Market by Region
• 10.3 Global Infectious Disease Market by Region
• 10.4 Global Neurological Disorders Market by Region
• 10.5 Global Other Therapeutic Area Market by Region

Chapter 11. Global Biosimulation Market by Region

• 11.1 North America Biosimulation Market
  • 11.1.1 North America Biosimulation Market by Product
    • 11.1.1.1 North America Software Market by Region
    • 11.1.1.2 North America Biosimulation Market by Software Type
      • 11.1.1.2.1 North America Molecular Modeling & Simulation Software Market by Country
      • 11.1.1.2.2 North America Clinical Trial Design Software Market by Country
      • 11.1.1.2.3 North America PK/PD Modeling and Simulation Software Market by Country
      • 11.1.1.2.4 North America Pbpk Modeling and Simulation Software Market by Country
      • 11.1.1.2.5 North America Toxicity Prediction Software Market by Country
      • 11.1.1.2.6 North America Other Software Type Market by Country
    • 11.1.1.3 North America Services Market by Region
    • 11.1.1.4 North America Biosimulation Market by Services Type
      • 11.1.1.4.1 North America Contract Services Market by Country
      • 11.1.1.4.2 North America Consulting Market by Country
      • 11.1.1.4.3 North America Other Services Type Market by Country
  • 11.1.2 North America Biosimulation Market by Pricing Model
    • 11.1.2.1 North America License-based Model Market by Country
    • 11.1.2.2 North America Subscription-based Model Market by Country
    • 11.1.2.3 North America Service-based Model Market by Country
    • 11.1.2.4 North America Pay Per Use Model Market by Country
  • 11.1.3 North America Biosimulation Market by End Use
    • 11.1.3.1 North America Life Sciences Companies Market by Country
    • 11.1.3.2 North America Academic Research Institutions Market by Country
    • 11.1.3.3 North America Other End Use Market by Country
  • 11.1.4 North America Biosimulation Market by Application
    • 11.1.4.1 North America Drug Discovery & Development Market by Country
    • 11.1.4.2 North America Disease Modeling Market by Country
    • 11.1.4.3 North America Other Application Market by Country
  • 11.1.5 North America Biosimulation Market by Deployment Model
    • 11.1.5.1 North America Cloud-based Market by Country
    • 11.1.5.2 North America On-premises Market by Country
    • 11.1.5.3 North America Hybrid Model Market by Country
  • 11.1.6 North America Biosimulation Market by Therapeutic Area
    • 11.1.6.1 North America Oncology Market by Country
    • 11.1.6.2 North America Cardiovascular Disease Market by Country
    • 11.1.6.3 North America Infectious Disease Market by Country
    • 11.1.6.4 North America Neurological Disorders Market by Country
    • 11.1.6.5 North America Other Therapeutic Area Market by Country
  • 11.1.7 North America Biosimulation Market by Country
    • 11.1.7.1 US Biosimulation Market
      • 11.1.7.1.1 US Biosimulation Market by Product
        • 11.1.7.1.1.1 US Biosimulation Market by Software Type
        • 11.1.7.1.1.2 US Biosimulation Market by Services Type
      • 11.1.7.1.2 US Biosimulation Market by Pricing Model
      • 11.1.7.1.3 US Biosimulation Market by End Use
      • 11.1.7.1.4 US Biosimulation Market by Application
      • 11.1.7.1.5 US Biosimulation Market by Deployment Model
      • 11.1.7.1.6 US Biosimulation Market by Therapeutic Area
    • 11.1.7.2 Canada Biosimulation Market
      • 11.1.7.2.1 Canada Biosimulation Market by Product
        • 11.1.7.2.1.1 Canada Biosimulation Market by Software Type
        • 11.1.7.2.1.2 Canada Biosimulation Market by Services Type
      • 11.1.7.2.2 Canada Biosimulation Market by Pricing Model
      • 11.1.7.2.3 Canada Biosimulation Market by End Use
      • 11.1.7.2.4 Canada Biosimulation Market by Application
      • 11.1.7.2.5 Canada Biosimulation Market by Deployment Model
      • 11.1.7.2.6 Canada Biosimulation Market by Therapeutic Area
    • 11.1.7.3 Mexico Biosimulation Market
      • 11.1.7.3.1 Mexico Biosimulation Market by Product
        • 11.1.7.3.1.1 Mexico Biosimulation Market by Software Type
        • 11.1.7.3.1.2 Mexico Biosimulation Market by Services Type
      • 11.1.7.3.2 Mexico Biosimulation Market by Pricing Model
      • 11.1.7.3.3 Mexico Biosimulation Market by End Use
      • 11.1.7.3.4 Mexico Biosimulation Market by Application
      • 11.1.7.3.5 Mexico Biosimulation Market by Deployment Model
      • 11.1.7.3.6 Mexico Biosimulation Market by Therapeutic Area
    • 11.1.7.4 Rest of North America Biosimulation Market
      • 11.1.7.4.1 Rest of North America Biosimulation Market by Product
        • 11.1.7.4.1.1 Rest of North America Biosimulation Market by Software Type
        • 11.1.7.4.1.2 Rest of North America Biosimulation Market by Services Type
      • 11.1.7.4.2 Rest of North America Biosimulation Market by Pricing Model
      • 11.1.7.4.3 Rest of North America Biosimulation Market by End Use
      • 11.1.7.4.4 Rest of North America Biosimulation Market by Application
      • 11.1.7.4.5 Rest of North America Biosimulation Market by Deployment Model
      • 11.1.7.4.6 Rest of North America Biosimulation Market by Therapeutic Area
• 11.2 Europe Biosimulation Market
  • 11.2.1 Europe Biosimulation Market by Product
    • 11.2.1.1 Europe Software Market by Country
    • 11.2.1.2 Europe Biosimulation Market by Software Type
      • 11.2.1.2.1 Europe Molecular Modeling & Simulation Software Market by Country
      • 11.2.1.2.2 Europe Clinical Trial Design Software Market by Country
      • 11.2.1.2.3 Europe PK/PD Modeling and Simulation Software Market by Country
      • 11.2.1.2.4 Europe Pbpk Modeling and Simulation Software Market by Country
      • 11.2.1.2.5 Europe Toxicity Prediction Software Market by Country
      • 11.2.1.2.6 Europe Other Software Type Market by Country
    • 11.2.1.3 Europe Services Market by Country
    • 11.2.1.4 Europe Biosimulation Market by Services Type
      • 11.2.1.4.1 Europe Contract Services Market by Country
      • 11.2.1.4.2 Europe Consulting Market by Country
      • 11.2.1.4.3 Europe Other Services Type Market by Country
  • 11.2.2 Europe Biosimulation Market by Pricing Model
    • 11.2.2.1 Europe License-based Model Market by Country
    • 11.2.2.2 Europe Subscription-based Model Market by Country
    • 11.2.2.3 Europe Service-based Model Market by Country
    • 11.2.2.4 Europe Pay Per Use Model Market by Country
  • 11.2.3 Europe Biosimulation Market by End Use
    • 11.2.3.1 Europe Life Sciences Companies Market by Country
    • 11.2.3.2 Europe Academic Research Institutions Market by Country
    • 11.2.3.3 Europe Other End Use Market by Country
  • 11.2.4 Europe Biosimulation Market by Application
    • 11.2.4.1 Europe Drug Discovery & Development Market by Country
    • 11.2.4.2 Europe Disease Modeling Market by Country
    • 11.2.4.3 Europe Other Application Market by Country
  • 11.2.5 Europe Biosimulation Market by Deployment Model
    • 11.2.5.1 Europe Cloud-based Market by Country
    • 11.2.5.2 Europe On-premises Market by Country
    • 11.2.5.3 Europe Hybrid Model Market by Country
  • 11.2.6 Europe Biosimulation Market by Therapeutic Area
    • 11.2.6.1 Europe Oncology Market by Country
    • 11.2.6.2 Europe Cardiovascular Disease Market by Country
    • 11.2.6.3 Europe Infectious Disease Market by Country
    • 11.2.6.4 Europe Neurological Disorders Market by Country
    • 11.2.6.5 Europe Other Therapeutic Area Market by Country
  • 11.2.7 Europe Biosimulation Market by Country
    • 11.2.7.1 Germany Biosimulation Market
      • 11.2.7.1.1 Germany Biosimulation Market by Product
        • 11.2.7.1.1.1 Germany Biosimulation Market by Software Type
        • 11.2.7.1.1.2 Germany Biosimulation Market by Services Type
      • 11.2.7.1.2 Germany Biosimulation Market by Pricing Model
      • 11.2.7.1.3 Germany Biosimulation Market by End Use
      • 11.2.7.1.4 Germany Biosimulation Market by Application
      • 11.2.7.1.5 Germany Biosimulation Market by Deployment Model
      • 11.2.7.1.6 Germany Biosimulation Market by Therapeutic Area
    • 11.2.7.2 UK Biosimulation Market
      • 11.2.7.2.1 UK Biosimulation Market by Product
        • 11.2.7.2.1.1 UK Biosimulation Market by Software Type
        • 11.2.7.2.1.2 UK Biosimulation Market by Services Type
      • 11.2.7.2.2 UK Biosimulation Market by Pricing Model
      • 11.2.7.2.3 UK Biosimulation Market by End Use
      • 11.2.7.2.4 UK Biosimulation Market by Application
      • 11.2.7.2.5 UK Biosimulation Market by Deployment Model
      • 11.2.7.2.6 UK Biosimulation Market by Therapeutic Area
    • 11.2.7.3 France Biosimulation Market
      • 11.2.7.3.1 France Biosimulation Market by Product
        • 11.2.7.3.1.1 France Biosimulation Market by Software Type
        • 11.2.7.3.1.2 France Biosimulation Market by Services Type
      • 11.2.7.3.2 France Biosimulation Market by Pricing Model
      • 11.2.7.3.3 France Biosimulation Market by End Use
      • 11.2.7.3.4 France Biosimulation Market by Application
      • 11.2.7.3.5 France Biosimulation Market by Deployment Model
      • 11.2.7.3.6 France Biosimulation Market by Therapeutic Area
    • 11.2.7.4 Russia Biosimulation Market
      • 11.2.7.4.1 Russia Biosimulation Market by Product
        • 11.2.7.4.1.1 Russia Biosimulation Market by Software Type
        • 11.2.7.4.1.2 Russia Biosimulation Market by Services Type
      • 11.2.7.4.2 Russia Biosimulation Market by Pricing Model
      • 11.2.7.4.3 Russia Biosimulation Market by End Use
      • 11.2.7.4.4 Russia Biosimulation Market by Application
      • 11.2.7.4.5 Russia Biosimulation Market by Deployment Model
      • 11.2.7.4.6 Russia Biosimulation Market by Therapeutic Area
    • 11.2.7.5 Spain Biosimulation Market
      • 11.2.7.5.1 Spain Biosimulation Market by Product
        • 11.2.7.5.1.1 Spain Biosimulation Market by Software Type
        • 11.2.7.5.1.2 Spain Biosimulation Market by Services Type
      • 11.2.7.5.2 Spain Biosimulation Market by Pricing Model
      • 11.2.7.5.3 Spain Biosimulation Market by End Use
      • 11.2.7.5.4 Spain Biosimulation Market by Application
      • 11.2.7.5.5 Spain Biosimulation Market by Deployment Model
      • 11.2.7.5.6 Spain Biosimulation Market by Therapeutic Area
    • 11.2.7.6 Italy Biosimulation Market
      • 11.2.7.6.1 Italy Biosimulation Market by Product
        • 11.2.7.6.1.1 Italy Biosimulation Market by Software Type
        • 11.2.7.6.1.2 Italy Biosimulation Market by Services Type
      • 11.2.7.6.2 Italy Biosimulation Market by Pricing Model
      • 11.2.7.6.3 Italy Biosimulation Market by End Use
      • 11.2.7.6.4 Italy Biosimulation Market by Application
      • 11.2.7.6.5 Italy Biosimulation Market by Deployment Model
      • 11.2.7.6.6 Italy Biosimulation Market by Therapeutic Area
    • 11.2.7.7 Rest of Europe Biosimulation Market
      • 11.2.7.7.1 Rest of Europe Biosimulation Market by Product
        • 11.2.7.7.1.1 Rest of Europe Biosimulation Market by Software Type
        • 11.2.7.7.1.2 Rest of Europe Biosimulation Market by Services Type
      • 11.2.7.7.2 Rest of Europe Biosimulation Market by Pricing Model
      • 11.2.7.7.3 Rest of Europe Biosimulation Market by End Use
      • 11.2.7.7.4 Rest of Europe Biosimulation Market by Application
      • 11.2.7.7.5 Rest of Europe Biosimulation Market by Deployment Model
      • 11.2.7.7.6 Rest of Europe Biosimulation Market by Therapeutic Area
• 11.3 Asia Pacific Biosimulation Market
  • 11.3.1 Asia Pacific Biosimulation Market by Product
    • 11.3.1.1 Asia Pacific Software Market by Country
    • 11.3.1.2 Asia Pacific Biosimulation Market by Software Type
      • 11.3.1.2.1 Asia Pacific Molecular Modeling & Simulation Software Market by Country
      • 11.3.1.2.2 Asia Pacific Clinical Trial Design Software Market by Country
      • 11.3.1.2.3 Asia Pacific PK/PD Modeling and Simulation Software Market by Country
      • 11.3.1.2.4 Asia Pacific Pbpk Modeling and Simulation Software Market by Country
      • 11.3.1.2.5 Asia Pacific Toxicity Prediction Software Market by Country
      • 11.3.1.2.6 Asia Pacific Other Software Type Market by Country
    • 11.3.1.3 Asia Pacific Services Market by Country
    • 11.3.1.4 Asia Pacific Biosimulation Market by Services Type
      • 11.3.1.4.1 Asia Pacific Contract Services Market by Country
      • 11.3.1.4.2 Asia Pacific Consulting Market by Country
      • 11.3.1.4.3 Asia Pacific Other Services Type Market by Country
  • 11.3.2 Asia Pacific Biosimulation Market by Pricing Model
    • 11.3.2.1 Asia Pacific License-based Model Market by Country
    • 11.3.2.2 Asia Pacific Subscription-based Model Market by Country
    • 11.3.2.3 Asia Pacific Service-based Model Market by Country
    • 11.3.2.4 Asia Pacific Pay Per Use Model Market by Country
  • 11.3.3 Asia Pacific Biosimulation Market by End Use
    • 11.3.3.1 Asia Pacific Life Sciences Companies Market by Country
    • 11.3.3.2 Asia Pacific Academic Research Institutions Market by Country
    • 11.3.3.3 Asia Pacific Other End Use Market by Country
  • 11.3.4 Asia Pacific Biosimulation Market by Application
    • 11.3.4.1 Asia Pacific Drug Discovery & Development Market by Country
    • 11.3.4.2 Asia Pacific Disease Modeling Market by Country
    • 11.3.4.3 Asia Pacific Other Application Market by Country
  • 11.3.5 Asia Pacific Biosimulation Market by Deployment Model
    • 11.3.5.1 Asia Pacific Cloud-based Market by Country
    • 11.3.5.2 Asia Pacific On-premises Market by Country
    • 11.3.5.3 Asia Pacific Hybrid Model Market by Country
  • 11.3.6 Asia Pacific Biosimulation Market by Therapeutic Area
    • 11.3.6.1 Asia Pacific Oncology Market by Country
    • 11.3.6.2 Asia Pacific Cardiovascular Disease Market by Country
    • 11.3.6.3 Asia Pacific Infectious Disease Market by Country
    • 11.3.6.4 Asia Pacific Neurological Disorders Market by Country
    • 11.3.6.5 Asia Pacific Other Therapeutic Area Market by Country
  • 11.3.7 Asia Pacific Biosimulation Market by Country
    • 11.3.7.1 China Biosimulation Market
      • 11.3.7.1.1 China Biosimulation Market by Product
        • 11.3.7.1.1.1 China Biosimulation Market by Software Type
        • 11.3.7.1.1.2 China Biosimulation Market by Services Type
      • 11.3.7.1.2 China Biosimulation Market by Pricing Model
      • 11.3.7.1.3 China Biosimulation Market by End Use
      • 11.3.7.1.4 China Biosimulation Market by Application
      • 11.3.7.1.5 China Biosimulation Market by Deployment Model
      • 11.3.7.1.6 China Biosimulation Market by Therapeutic Area
    • 11.3.7.2 Japan Biosimulation Market
      • 11.3.7.2.1 Japan Biosimulation Market by Product
        • 11.3.7.2.1.1 Japan Biosimulation Market by Software Type
        • 11.3.7.2.1.2 Japan Biosimulation Market by Services Type
      • 11.3.7.2.2 Japan Biosimulation Market by Pricing Model
      • 11.3.7.2.3 Japan Biosimulation Market by End Use
      • 11.3.7.2.4 Japan Biosimulation Market by Application
      • 11.3.7.2.5 Japan Biosimulation Market by Deployment Model
      • 11.3.7.2.6 Japan Biosimulation Market by Therapeutic Area
    • 11.3.7.3 India Biosimulation Market
      • 11.3.7.3.1 India Biosimulation Market by Product
        • 11.3.7.3.1.1 India Biosimulation Market by Software Type
        • 11.3.7.3.1.2 India Biosimulation Market by Services Type
      • 11.3.7.3.2 India Biosimulation Market by Pricing Model
      • 11.3.7.3.3 India Biosimulation Market by End Use
      • 11.3.7.3.4 India Biosimulation Market by Application
      • 11.3.7.3.5 India Biosimulation Market by Deployment Model
      • 11.3.7.3.6 India Biosimulation Market by Therapeutic Area
    • 11.3.7.4 South Korea Biosimulation Market
      • 11.3.7.4.1 South Korea Biosimulation Market by Product
        • 11.3.7.4.1.1 South Korea Biosimulation Market by Software Type
        • 11.3.7.4.1.2 South Korea Biosimulation Market by Services Type
      • 11.3.7.4.2 South Korea Biosimulation Market by Pricing Model
      • 11.3.7.4.3 South Korea Biosimulation Market by End Use
      • 11.3.7.4.4 South Korea Biosimulation Market by Application
      • 11.3.7.4.5 South Korea Biosimulation Market by Deployment Model
      • 11.3.7.4.6 South Korea Biosimulation Market by Therapeutic Area
    • 11.3.7.5 Singapore Biosimulation Market
      • 11.3.7.5.1 Singapore Biosimulation Market by Product
        • 11.3.7.5.1.1 Singapore Biosimulation Market by Software Type
        • 11.3.7.5.1.2 Singapore Biosimulation Market by Services Type
      • 11.3.7.5.2 Singapore Biosimulation Market by Pricing Model
      • 11.3.7.5.3 Singapore Biosimulation Market by End Use
      • 11.3.7.5.4 Singapore Biosimulation Market by Application
      • 11.3.7.5.5 Singapore Biosimulation Market by Deployment Model
      • 11.3.7.5.6 Singapore Biosimulation Market by Therapeutic Area
    • 11.3.7.6 Malaysia Biosimulation Market
      • 11.3.7.6.1 Malaysia Biosimulation Market by Product
        • 11.3.7.6.1.1 Malaysia Biosimulation Market by Software Type
        • 11.3.7.6.1.2 Malaysia Biosimulation Market by Services Type
      • 11.3.7.6.2 Malaysia Biosimulation Market by Pricing Model
      • 11.3.7.6.3 Malaysia Biosimulation Market by End Use
      • 11.3.7.6.4 Malaysia Biosimulation Market by Application
      • 11.3.7.6.5 Malaysia Biosimulation Market by Deployment Model
      • 11.3.7.6.6 Malaysia Biosimulation Market by Therapeutic Area
    • 11.3.7.7 Rest of Asia Pacific Biosimulation Market
      • 11.3.7.7.1 Rest of Asia Pacific Biosimulation Market by Product
        • 11.3.7.7.1.1 Rest of Asia Pacific Biosimulation Market by Software Type
        • 11.3.7.7.1.2 Rest of Asia Pacific Biosimulation Market by Services Type
      • 11.3.7.7.2 Rest of Asia Pacific Biosimulation Market by Pricing Model
      • 11.3.7.7.3 Rest of Asia Pacific Biosimulation Market by End Use
      • 11.3.7.7.4 Rest of Asia Pacific Biosimulation Market by Application
      • 11.3.7.7.5 Rest of Asia Pacific Biosimulation Market by Deployment Model
      • 11.3.7.7.6 Rest of Asia Pacific Biosimulation Market by Therapeutic Area
• 11.4 LAMEA Biosimulation Market
  • 11.4.1 LAMEA Biosimulation Market by Product
    • 11.4.1.1 LAMEA Software Market by Country
    • 11.4.1.2 LAMEA Biosimulation Market by Software Type
      • 11.4.1.2.1 LAMEA Molecular Modeling & Simulation Software Market by Country
      • 11.4.1.2.2 LAMEA Clinical Trial Design Software Market by Country
      • 11.4.1.2.3 LAMEA PK/PD Modeling and Simulation Software Market by Country
      • 11.4.1.2.4 LAMEA Pbpk Modeling and Simulation Software Market by Country
      • 11.4.1.2.5 LAMEA Toxicity Prediction Software Market by Country
      • 11.4.1.2.6 LAMEA Other Software Type Market by Country
    • 11.4.1.3 LAMEA Services Market by Country
    • 11.4.1.4 LAMEA Biosimulation Market by Services Type
      • 11.4.1.4.1 LAMEA Contract Services Market by Country
      • 11.4.1.4.2 LAMEA Consulting Market by Country
      • 11.4.1.4.3 LAMEA Other Services Type Market by Country
  • 11.4.2 LAMEA Biosimulation Market by Pricing Model
    • 11.4.2.1 LAMEA License-based Model Market by Country
    • 11.4.2.2 LAMEA Subscription-based Model Market by Country
    • 11.4.2.3 LAMEA Service-based Model Market by Country
    • 11.4.2.4 LAMEA Pay Per Use Model Market by Country
  • 11.4.3 LAMEA Biosimulation Market by End Use
    • 11.4.3.1 LAMEA Life Sciences Companies Market by Country
    • 11.4.3.2 LAMEA Academic Research Institutions Market by Country
    • 11.4.3.3 LAMEA Other End Use Market by Country
  • 11.4.4 LAMEA Biosimulation Market by Application
    • 11.4.4.1 LAMEA Drug Discovery & Development Market by Country
    • 11.4.4.2 LAMEA Disease Modeling Market by Country
    • 11.4.4.3 LAMEA Other Application Market by Country
  • 11.4.5 LAMEA Biosimulation Market by Deployment Model
    • 11.4.5.1 LAMEA Cloud-based Market by Country
    • 11.4.5.2 LAMEA On-premises Market by Country
    • 11.4.5.3 LAMEA Hybrid Model Market by Country
  • 11.4.6 LAMEA Biosimulation Market by Therapeutic Area
    • 11.4.6.1 LAMEA Oncology Market by Country
    • 11.4.6.2 LAMEA Cardiovascular Disease Market by Country
    • 11.4.6.3 LAMEA Infectious Disease Market by Country
    • 11.4.6.4 LAMEA Neurological Disorders Market by Country
    • 11.4.6.5 LAMEA Other Therapeutic Area Market by Country
  • 11.4.7 LAMEA Biosimulation Market by Country
    • 11.4.7.1 Brazil Biosimulation Market
      • 11.4.7.1.1 Brazil Biosimulation Market by Product
        • 11.4.7.1.1.1 Brazil Biosimulation Market by Software Type
        • 11.4.7.1.1.2 Brazil Biosimulation Market by Services Type
      • 11.4.7.1.2 Brazil Biosimulation Market by Pricing Model
      • 11.4.7.1.3 Brazil Biosimulation Market by End Use
      • 11.4.7.1.4 Brazil Biosimulation Market by Application
      • 11.4.7.1.5 Brazil Biosimulation Market by Deployment Model
      • 11.4.7.1.6 Brazil Biosimulation Market by Therapeutic Area
    • 11.4.7.2 Argentina Biosimulation Market
      • 11.4.7.2.1 Argentina Biosimulation Market by Product
        • 11.4.7.2.1.1 Argentina Biosimulation Market by Software Type
        • 11.4.7.2.1.2 Argentina Biosimulation Market by Services Type
      • 11.4.7.2.2 Argentina Biosimulation Market by Pricing Model
      • 11.4.7.2.3 Argentina Biosimulation Market by End Use
      • 11.4.7.2.4 Argentina Biosimulation Market by Application
      • 11.4.7.2.5 Argentina Biosimulation Market by Deployment Model
      • 11.4.7.2.6 Argentina Biosimulation Market by Therapeutic Area
    • 11.4.7.3 UAE Biosimulation Market
      • 11.4.7.3.1 UAE Biosimulation Market by Product
        • 11.4.7.3.1.1 UAE Biosimulation Market by Software Type
        • 11.4.7.3.1.2 UAE Biosimulation Market by Services Type
      • 11.4.7.3.2 UAE Biosimulation Market by Pricing Model
      • 11.4.7.3.3 UAE Biosimulation Market by End Use
      • 11.4.7.3.4 UAE Biosimulation Market by Application
      • 11.4.7.3.5 UAE Biosimulation Market by Deployment Model
      • 11.4.7.3.6 UAE Biosimulation Market by Therapeutic Area
    • 11.4.7.4 Saudi Arabia Biosimulation Market
      • 11.4.7.4.1 Saudi Arabia Biosimulation Market by Product
        • 11.4.7.4.1.1 Saudi Arabia Biosimulation Market by Software Type
        • 11.4.7.4.1.2 Saudi Arabia Biosimulation Market by Services Type
      • 11.4.7.4.2 Saudi Arabia Biosimulation Market by Pricing Model
      • 11.4.7.4.3 Saudi Arabia Biosimulation Market by End Use
      • 11.4.7.4.4 Saudi Arabia Biosimulation Market by Application
      • 11.4.7.4.5 Saudi Arabia Biosimulation Market by Deployment Model
      • 11.4.7.4.6 Saudi Arabia Biosimulation Market by Therapeutic Area
    • 11.4.7.5 South Africa Biosimulation Market
      • 11.4.7.5.1 South Africa Biosimulation Market by Product
        • 11.4.7.5.1.1 South Africa Biosimulation Market by Software Type
        • 11.4.7.5.1.2 South Africa Biosimulation Market by Services Type
      • 11.4.7.5.2 South Africa Biosimulation Market by Pricing Model
      • 11.4.7.5.3 South Africa Biosimulation Market by End Use
      • 11.4.7.5.4 South Africa Biosimulation Market by Application
      • 11.4.7.5.5 South Africa Biosimulation Market by Deployment Model
      • 11.4.7.5.6 South Africa Biosimulation Market by Therapeutic Area
    • 11.4.7.6 Nigeria Biosimulation Market
      • 11.4.7.6.1 Nigeria Biosimulation Market by Product
        • 11.4.7.6.1.1 Nigeria Biosimulation Market by Software Type
        • 11.4.7.6.1.2 Nigeria Biosimulation Market by Services Type
      • 11.4.7.6.2 Nigeria Biosimulation Market by Pricing Model
      • 11.4.7.6.3 Nigeria Biosimulation Market by End Use
      • 11.4.7.6.4 Nigeria Biosimulation Market by Application
      • 11.4.7.6.5 Nigeria Biosimulation Market by Deployment Model
      • 11.4.7.6.6 Nigeria Biosimulation Market by Therapeutic Area
    • 11.4.7.7 Rest of LAMEA Biosimulation Market
      • 11.4.7.7.1 Rest of LAMEA Biosimulation Market by Product
        • 11.4.7.7.1.1 Rest of LAMEA Biosimulation Market by Software Type
        • 11.4.7.7.1.2 Rest of LAMEA Biosimulation Market by Services Type
      • 11.4.7.7.2 Rest of LAMEA Biosimulation Market by Pricing Model
      • 11.4.7.7.3 Rest of LAMEA Biosimulation Market by End Use
      • 11.4.7.7.4 Rest of LAMEA Biosimulation Market by Application
      • 11.4.7.7.5 Rest of LAMEA Biosimulation Market by Deployment Model
      • 11.4.7.7.6 Rest of LAMEA Biosimulation Market by Therapeutic Area

Chapter 12. Company Profiles

• 12.1 Certara, Inc.
  • 12.1.1 Company Overview
  • 12.1.2 Financial Analysis
  • 12.1.3 Regional Analysis
  • 12.1.4 Research & Development Expenses
  • 12.1.5 Recent strategies and developments:
    • 12.1.5.1 Product Launches and Product Expansions:
    • 12.1.5.2 Acquisition and Mergers:
  • 12.1.6 SWOT Analysis
• 12.2 Dassault Systemes SE
  • 12.2.1 Company Overview
  • 12.2.2 Financial Analysis
  • 12.2.3 Regional Analysis
  • 12.2.4 Research & Development Expense
  • 12.2.5 SWOT Analysis
• 12.3 Advanced Chemistry Development, Inc.
  • 12.3.1 Company Overview
• 12.4 Genedata AG (Danaher Corporation)
  • 12.4.1 Company Overview
  • 12.4.2 Financial Analysis
  • 12.4.3 Segmental and Regional Analysis
  • 12.4.4 Research & Development Expense
  • 12.4.5 Recent strategies and developments:
    • 12.4.5.1 Partnerships, Collaborations, and Agreements:
• 12.5 Instem Group of Companies
  • 12.5.1 Company Overview
• 12.6 Chemical Computing Group ULC
  • 12.6.1 Company Overview
• 12.7 Simulations Plus, Inc.
  • 12.7.1 Company Overview
  • 12.7.2 Financial Analysis
  • 12.7.3 Segmental and Regional Analysis
  • 12.7.4 Research & Development Expenses
  • 12.7.5 Recent strategies and developments:
    • 12.7.5.1 Partnerships, Collaborations, and Agreements:
    • 12.7.5.2 Product Launches and Product Expansions:
    • 12.7.5.3 Acquisition and Mergers:
  • 12.7.6 SWOT Analysis
• 12.8 Schrodinger, Inc.
  • 12.8.1 Company Overview
  • 12.8.2 Financial Analysis
  • 12.8.3 Segmental and Regional Analysis
  • 12.8.4 Research & Development Expenses
• 12.9 PPD, Inc. (Thermo Fisher Scientific, Inc.)
  • 12.9.1 Company Overview
  • 12.9.2 Financial Analysis
  • 12.9.3 Segmental and Regional Analysis
  • 12.9.4 Research & Development Expenses
• 12.10. Physiomics Plc
  • 12.10.1 Company Overview
  • 12.10.2 Financial Analysis

Chapter 13. Winning Imperative of Biosimulation Market